Induced pluripotent stem (iPS) cells, which are generated from somatic cells, are expected to be a hopeful source for cell therapy to treat intractable diseases due to its unlimited proliferation potential, differentiation potentials and the capability of autotransplantation characteristics. In this review, we have summarized the extension of iPS cell researches into cell therapy and the new researches associated with iPS cell technology. However, transplantation of iPS cell-derived tissue is considered to have a risk of tumorigenesis which is one of the major hurdles of using pluripotent stem cell in clinical application. This review is also focused on new strategies for reducing a risk of tumorigenesis.